MDLinx: The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to low… http://bit.ly/9nbLj2 #oncology

MDLinx: The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to low… http://bit.ly/9nbLj2 #oncology

Related posts:

1. MDLinx: Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newl… http://bit.ly/9YmCVW #oncology
2. MDLinx: Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with c… http://bit.ly/dlZ31n #oncology
3. MDLinx: Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer: Journal… http://bit.ly/ara9NO #oncology